AIM ImmunoTech Receives IND Clearance from the US FDA to Advance its Phase II Study of Ampligen^® for the Treatment of Locally Advanced Pancreatic Cancer

AIM ImmunoTech, Inc. announced it has received notification from the FDA that the FDA’s Clinical Hold on AIM’s investigational new drug (IND) application for a Phase II study of Ampligen as a therapy for locally advanced pancreatic cancer has been lifted and the company may proceed with the study.